John Crowley - Amicus Therapeutics Insider

FOLD -- USA Stock  

USD 10.24  0.50  4.66%

Mr. John F. Crowley J.D. is the Chairman of the Board and Chief Executive Officer of Amicus Therapeutics, Inc. Mr. Crowley has also served as a director of Amicus since August 2004, with the exception of the period from September 2006 to March 2007 when he was in active duty service in the United States Navy . Mr. Crowley was President and Chief Executive Officer of Orexigen Therapeutics, Inc. from September 2003 to December 2004. He was President and Chief Executive Officer of Novazyme Pharmaceuticals, Inc., from March 2000 until that company was acquired by Genzyme Corporationrationration in September 2001 thereafter he served as Senior Vice President of Genzyme Therapeutics until December 2002
Age: 49  Chairman Since 2011  MBA    
Crowley received a B.S. degree in Foreign Service from Georgetown University School of Foreign Service, a J.D. from the University of Notre Dame Law School, and an M.B.A. from Harvard Business School.

John Crowley Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of (25.62) % which means that it has lost $25.62 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (82.89) % meaning that it created substantial loss on money invested by shareholders.
The company currently holds 318.81 M in liabilities with Debt to Equity (D/E) ratio of 77.5 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Amicus Therapeutics has Current Ratio of 8.94 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Similar Executives

Found 11 records


Marc TessierLavignecDenali Therapeutics
Patrick SoonShiongNantKwest
Thomas MeyerAuris Medical Holding AG
Arnold OronskyDynavax Technologies Corporatio
Vernon LoboEquillium
Paul ManningDova Pharmaceuticals
John AplinEndocyte
Yuen KamChina Cord Blood Corporation
James HealyAuris Medical Holding AG
Steven GorlinNantKwest
David MaddenDicerna Pharmaceuticals

Entity Summary

Amicus Therapeutics, Inc., a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. Amicus Therapeutics, Inc. was founded in 2002 and is headquartered in Cranbury, New Jersey. Amicus Therapeutics operates under Biotechnology classification in USA and is traded on BATS Exchange. It employs 325 people.Amicus Therapeutics (FOLD) is traded on BATS Exchange in USA. It is located in New Jersey U.S.A and employs 325 people. Amicus Therapeutics is listed under Pharmaceutical Products category by Fama And French industry classification.

Amicus Therapeutics Leadership Team

Hung Do, Senior Vice President - Discovery Biology
Robert Essner, Independent Director
John Kirk, Vice President - Regulatory Affairs
Andrew Mulberg, Vice President - Regulatory Strategy
Craig Wheeler, Independent Director
Daphne Quimi, Principal Accounting Officer, VP of Fin. and Corporate Controller
Bradley Campbell, Pres and COO
Enrique Dilone, Vice President - Technical Operations
John Crowley, Chairman and CEO
Dipal Doshi, Senior Vice President - Business Planning and Development
Mark Baldry, Vice President of Global Marketing
Margaret McGlynn, Independent Director
Samantha Prout, Principal Accounting Officer, Controller
Kenneth Peist, Vice President - Legal and Intellectual Property
Ken Valenzano, Senior Vice President - Preclinical Research
Ted Love, Independent Director
Jay Barth, Chief Medical Officer
Jayne Gershkowitz, Vice President - Patient Advocacy & Public Policy
Donald Hayden, Lead Independent Director
Michael Raab, Independent Director
Sara Pellegrino, IR Contact Officer
Willem Weperen, Regional Vice President and Country Manager, International
Sol Barer, Independent Director
Julie Yu, Vice President - Clinical Operations and Data Management
William Baird, CFO
David Allsop, Senior Vice President - International
Lynn Bleil, Independent Director
Ellen Rosenberg, General Counsel and Corporate Secretary
Glenn Sblendorio, Independent Director
Jeffrey Castelli, Vice President - Program and Portfolio Management
Kurt Andrews, Senior Vice President - Human Resources

Stock Performance Indicators

Current Sentiment - FOLD

Amicus Therapeutics Investor Sentiment

Most of Macroaxis users are currently bullish on Amicus Therapeutics. What is your sentiment towards investing in Amicus Therapeutics? Are you bullish or bearish?
98% Bullish
2% Bearish

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Additionally see Investing Opportunities. Please also try Content Syndication module to quickly integrate customizable finance content to your own investment portal.